Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di Dose-Risposta di ORKA-001 in Pazienti con Psoriasi a Placche da Moderata a Grave (EVERLAST-B)

3 novembre 2026 aggiornato da: Oruka Therapeutics, Inc.

Studio multicentrico, randomizzato, in doppio cieco, controllato con placebo, per la determinazione della dose di ORKA-001 in partecipanti con psoriasi a placche da moderata a grave

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.

The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.

The study will consist of 4 periods:

  • Screening Period of up to 6 weeks
  • Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
  • Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
  • Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.

Tipo di studio

Interventistico

Iscrizione (Stimato)

160

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • British Columbia
      • Surrey, British Columbia, Canada, V3R 6A7
        • Oruka Therapeutics Investigative Site
      • Surrey, British Columbia, Canada, V3V 0C6
        • Oruka Therapeutics Investigative Site
    • New Brunswick
      • Fredericton, New Brunswick, Canada, E3B 1G9
        • Oruka Therapeutics Investigative Site
    • Ontario
      • Ajax, Ontario, Canada, L1S 7K8
        • Oruka Therapeutics Investigative Site
      • Markham, Ontario, Canada, L3P 1X3
        • Oruka Therapeutics Investigative Site
      • Peterborough, Ontario, Canada, K9J 5K2
        • Oruka Therapeutics Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, HZX 2V1
        • Oruka Therapeutics Investigative Site
      • Québec, Quebec, Canada, G1V 4X7
        • Oruka Therapeutics Investigative Site
    • Baden-Wuerrtemberg
      • Heidelberg, Baden-Wuerrtemberg, Germania, 69120
        • Oruka Therapeutics Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Germania, 60590
        • Oruka Therapeutics Investigative Site
    • Lower Saxony
      • Bad Bentheim, Lower Saxony, Germania, 48455
        • Oruka Therapeutics Investigative Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Germania, 24105
        • Oruka Therapeutics Investigative Site
    • Barcelona
      • Badalona, Barcelona, Spagna, 08916
        • Oruka Therapeutics Investigative Site
      • Barcelona, Barcelona, Spagna, 08041
        • Oruka Therapeutics Investigative Site
    • Madrid
      • Madrid, Madrid, Spagna, 28002
        • Oruka Therapeutics Investigative Site
      • Madrid, Madrid, Spagna, 28046
        • Oruka Therapeutics Investigative Site
    • Arizona
      • Phoenix, Arizona, Stati Uniti, 85032
        • Oruka Therapeutics Investigative Site
    • Arkansas
      • North Little Rock, Arkansas, Stati Uniti, 72117
        • Oruka Therapeutics Investigative Site
    • California
      • Los Angeles, California, Stati Uniti, 90045
        • Oruka Therapeutics Investigative Site
      • Los Angeles, California, Stati Uniti, 90024
        • Oruka Therapeutics Investigative Site
      • San Diego, California, Stati Uniti, 92123
        • Oruka Therapeutics Investigative Site
    • Florida
      • Miami, Florida, Stati Uniti, 33126
        • Oruka Therapeutics Investigative Site
    • Illinois
      • Rolling Meadows, Illinois, Stati Uniti, 60008
        • Oruka Therapeutics Investigative Site
    • Indiana
      • Plainfield, Indiana, Stati Uniti, 46168
        • Oruka Therapeutics Investigative Site
    • Maryland
      • Rockville, Maryland, Stati Uniti, 20850
        • Oruka Therapeutics Investigative Site
    • New York
      • Kew Gardens, New York, Stati Uniti, 11415
        • Oruka Therapeutics Investigative Site
    • North Carolina
      • Chapel Hill, North Carolina, Stati Uniti, 27516
        • Oruka Therapeutics Investigative Site
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • Oruka Therapeutics Investigative Site
      • Mason, Ohio, Stati Uniti, 45040
        • Oruka Therapeutics Investigative Site
    • Oregon
      • Portland, Oregon, Stati Uniti, 97201
        • Oruka Therapeutics Investigative Site
      • Portland, Oregon, Stati Uniti, 97210
        • Oruka Therapeutics Investigative Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Oruka Therapeutics Investigative Site
    • Texas
      • Frisco, Texas, Stati Uniti, 75033
        • Oruka Therapeutics Investigative Site
      • Houston, Texas, Stati Uniti, 77004
        • Oruka Therapeutics Investigative Site
      • Webster, Texas, Stati Uniti, 77598
        • Oruka Therapeutics Investigative Site
    • Virginia
      • Norfolk, Virginia, Stati Uniti, 23502
        • Oruka Therapeutics Investigative Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Participants ≥ 18 years of age

  2. Have a diagnosis of plaque psoriasis for > 6 months

  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy

  5. Women of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known hypersensitivity to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: (Induction Period - Arm 1) ORKA-001

Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Sperimentale: (Induction Period - Arm 2) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Sperimentale: (Induction Period - Arm 3) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Comparatore placebo: (Induction Period - Arm 4) Placebo

Participants will receive Placebo per protocol Induction regimen.

Placebo administered by subcutaneous (SC) injection

Sperimentale: (Maintenance Period - Arm 1) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Sperimentale: (Maintenance Period - Arm 2) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Comparatore placebo: (Maintenance Period - Arm 3) Placebo

Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

Placebo administered by subcutaneous (SC) injection

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Lasso di tempo: Week 16

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Lasso di tempo: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Lasso di tempo: Week 16

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Lasso di tempo: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Lasso di tempo: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Lasso di tempo: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Lasso di tempo: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Lasso di tempo: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Lasso di tempo: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Lasso di tempo: Day 1 through Week 100

Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

Day 1 through Week 100

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

3 dicembre 2025

Completamento primario (Effettivo)

21 ottobre 2026

Completamento dello studio (Stimato)

1 dicembre 2028

Date di iscrizione allo studio

Primo inviato

16 dicembre 2025

Primo inviato che soddisfa i criteri di controllo qualità

16 dicembre 2025

Primo Inserito (Effettivo)

18 dicembre 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • ORKA-001-114

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .